|
The Metabolic Effects of Protease Inhibitors in HIV Infected Children Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on The Metabolic Effects of Protease Inhibitors in HIV Infected Children conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. The Metabolic Effects of Protease Inhibitors in HIV Infected Children Clinical research trials and The Metabolic Effects of Protease Inhibitors in HIV Infected Children medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like The Metabolic Effects of Protease Inhibitors in HIV Infected Children. The Metabolic Effects of Protease Inhibitors in HIV Infected Children Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a The Metabolic Effects of Protease Inhibitors in HIV Infected Children clinical trial. Participants frequently obtain the most expert healthcare available for their The Metabolic Effects of Protease Inhibitors in HIV Infected Children condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Metabolic Effects of Protease Inhibitors in HIV Infected Children  The Metabolic Effects of Protease Inhibitors in HIV Infected Children
The Metabolic Effects of Protease Inhibitors in HIV Infected Children
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Center for Research Resources (NCRR) , Pediatric AIDS Foundation
Synopsis: The use of protease inhibitors is increasing in HIV-infected children because this treatment has resulted in improved body weight, improved immune status and less hospitalizations. However, recent reports suggest that these drugs may also be associated with some negative side-effects, specifically a syndrome of diabetes and fat redistribution. Development of the fat redistribution/diabetes syndrome has recently been reported in HIV-infected children, as well as in adults. Diabetes is associated with complications such as increased heart disease, eye disease and loss of kidney function. Thus development of diabetes is a significant problem which could outweigh the benefits obtained by treating patients with protease inhibitors. One major cause of diabetes is lack of normal response to insulin (insulin resistance). Insulin resistance tends to be worse in family members where one or more parent has diabetes, and is also worse in certain ethnic groups. The first major purpose of our study is measure insulin resistance in HIV-infected children who do not take protease inhibitors, and compare our findings to those from patients who are treated with protease inhibitors. We will also follow patients newly treated with protease inhibitors for two years to evaluate changes in insulin sensitivity. These results will be correlated with each patient's family history of diabetes and with ethnicity, and should help us better predict which children are "at risk" for development of diabetes from protease inhibitor therapy. Children with HIV infection often have problems with gaining enough weight and with poor linear growth (height). One likely reason for this is the way their bodies use and store protein. The second purpose of our study is measure protein turnover and to correlate our findings with growth data. We also plan to study the effects of protease inhibitor therapy on protein turnover. We believe that these studies will provide knowledge to help clinicians formulate recommendations for nutritional and medical therapy.
Details:
Eligibility:
Study Type: Interventional, Prevention
Minimum Age/Maximum Age: 7 Years/18 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Inclusion criteria for HIV infected children- a) The participants may be either antiretroviral treatment naive, or experienced. Those individuals who are experienced will be treated with at least one new drug in addition to the protease inhibitor. The selection of the new antiretroviral regimen will be directed by a review of the patient's previous drug treatment history and/or the genetic or phenotypic characteristics of the patient's virus; b) We will recruit subjects from all CDC categories. Disease severity will subsequently be analyzed as a covariate; c) There will be no height, weight or other anthropometric inclusion criterion (these factors will be analyzed as covariates); d) All subjects will be studied when they have not had an acute superinfection for at least four weeks. - Inclusion criteria for controls- Control volunteers will be normal healthy children who are matched to the HIV infected population for age, weight and race. Normal health and non-HIV infected status will be determined by history and by medical record review. Ethical considerations preclude HIV testing in normal children. Separate informed consent and assent forms will be utilized for the control and HIV population. Exclusion Criteria: - Exclusion criteria for HIV infected children- Use of Megace@ or another progestational agent, use of anabolic steroids, acute superinfection - Exclusion criteria for controls- Previous medical history of any chronic disease or glucocorticoid use in the last six weeks. Adopted children who have no knowledge of family history.
Total Enrollment:
Location and Contact Information:
University of Texas Medical School, Dept. of Pediatrics
Houston, Texas, 77030
United States
University of Utah
Salt Lake City, Utah, 84132
United States
Additional Information:
Study ID Numbers: NCRR-M01RR02558-0130; M01RR02558
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004739
Other Hiv Infections Studies:
1. A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine
2. An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients with Progressive HIV Disease
3. Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
4. A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients
5. Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination with Nucleoside Analogs: A Rollover Study for ACTG 320
Related Studies:
Other HIV Infections Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
The Metabolic Effects of Protease Inhibitors in HIV Infected Children
|
|
|
|
|
|
|
|
